Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Tesla slides ahead of quarterly earnings scheduled for Tuesday, and Nvidia tumbles with the chip maker a victim of the ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Finding a new place to work is a job in and of itself, as anyone who’s gone job-seeking in the last three or so years can ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced ...

Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...